Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.59 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15823711 | 1.00 | BRPF1 (0.59) | BRPF1CREBBPBRD4TP53MAPT | |
| SCHEMBL16053338 | 0.93 | BRPF1 (0.59) | BRPF1CREBBPBRD4TP53MAPT | |
| SCHEMBL7170205 | 0.79 | BRPF1 (0.59) | BRPF1CREBBPBRD4POLBCMA1 | |
| SCHEMBL4863718 | 0.79 | BRPF1 (0.59) | BRPF1CREBBPBRD4MAPTGSK3B | |
| SCHEMBL7171052 | 0.79 | BRPF1 (0.59) | BRPF1CREBBPBRD4POLBCMA1 | |
| SCHEMBL7175133 | 0.79 | BRPF1 (0.59) | BRPF1CREBBPBRD4POLBCMA1 | |
| SCHEMBL16120451 | 0.79 | BRPF1 (0.59) | BRPF1CREBBPBRD4MAPTGSK3B | |
| SCHEMBL4860943 | 0.78 | TP53 (0.44) | BRD4TP53MAPTPOLBGABRA1 | |
| SCHEMBL28821831 | 0.78 | TP53 (0.44) | BRD4TP53MAPTPOLBGABRA1 | |
| SCHEMBL28821832 | 0.78 | TP53 (0.44) | BRD4TP53MAPTPOLBGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105198871-A | Quinoxalinone compounds as well as preparation methods and applications of quinoxalinone compounds | UNIV CHINA PHARMA | 2015-12-30 | — | — | CN | disclosed |
| WO-2014139983-A1 | [1,2,4]TRIAZOLO[4,3-A]QUINOXALINES AS DUAL PDE2/PDE10 INHIBITORS | H. LUNDBECK A/S (DK) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013034755-A1 | TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | disclosed |
| US-6794373-B2 | ADMINISTERING TO A FEMALE OF CHILD BEARING AGE OVER A PERIOD OF 28 CONSECUTIVE DAYS A FIRST PHASE OF FROM 18 TO 21 DAILY DOSAGE UNITS OF A PROGESTATIONAL AGENT, AND A SECOND PHASE OF FROM 1 TO 7 DAILY DOSAGE UNITS OF AN ANTIPROGESTIN AGENT | WYETH | 2004-09-21 | — | — | US | disclosed |
| US-20020151531-A1 | Contraceptive methods using benzimidazolones | LIGAND PHARMACEUTICALS INCORPORATED | 2002-10-17 | — | — | US | disclosed |
| US-20020115853-A1 | Benzimidazolones and analogues | WYETH | 2002-08-22 | — | — | US | disclosed |
| US-6423699-B1 | CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-07-23 | — | — | US | disclosed |
| US-6380235-B1 | USEFUL AS PROGESTERONE RECEPTOR AGONISTS AND ANTAGONISTS, USED FOR CONTRACEPTION, IN THERAPY OF FIBROIDS, ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER, AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151531-A1 | Contraceptive methods using benzimidazolones | PGR, GNRHR, NR4A1 | BRPF1 569/4885CREBBP 2696/4885BRD4 114/4885 |
| US-20020115853-A1 | Benzimidazolones and analogues | PGR, NR5A1, NR3C2 | BRPF1 759/4885CREBBP 2373/4885BRD4 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.